Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 22, 2009

Merck and DNDi Team Up to Fight Neglected Tropical Diseases

  • Merck & Co. and the Drugs for Neglected Diseases initiative (DNDi) entered into an agreement to support discovery and development of improved treatments for neglected tropical diseases (NTDs). Merck will contribute small molecule assets and related intellectual property via a nonexclusive, royalty-free license to DNDi to conduct early development programs for drug candidates for the treatment of NTDs like visceral leishmaniasis and Chagas disease.

    As part of the collaboration, Merck and DNDi will share joint intellectual property on drug candidates generated through early development. Merck will retain the option to undertake late clinical development and registration of drug candidates at its own expense or in partnership.

     


    ♦♦♦
    Related News

    MMV Takes Over Merck & Co.’s Early-Stage Antimalarial (Mar. 18, 2009)
    Nonprofit Organization Receives License for Anti-HIV Candidate from Merck & Co. (Mar. 11, 2008)



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »